Who Prioritizes Innovation? R&D Spending Compared for ADMA Biologics, Inc. and Bausch Health Companies Inc.

Comparing R&D Priorities: ADMA vs. Bausch Health

__timestampADMA Biologics, Inc.Bausch Health Companies Inc.
Wednesday, January 1, 20149517014246000000
Thursday, January 1, 20157015946582800000
Friday, January 1, 20167688238455000000
Sunday, January 1, 20176229587366000000
Monday, January 1, 20183926120414000000
Tuesday, January 1, 20192343848471000000
Wednesday, January 1, 20205907013452000000
Friday, January 1, 20213646060465000000
Saturday, January 1, 20223613764529000000
Sunday, January 1, 20233300000604000000
Loading chart...

Igniting the spark of knowledge

Innovation in Focus: A Tale of Two Companies

In the ever-evolving landscape of biotechnology and pharmaceuticals, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, ADMA Biologics, Inc. and Bausch Health Companies Inc. have demonstrated contrasting approaches to R&D investment. From 2014 to 2023, Bausch Health consistently allocated a significant portion of its resources to R&D, with expenditures peaking at approximately $604 million in 2023, marking a 146% increase from 2014. In contrast, ADMA Biologics' R&D spending showed a downward trend, decreasing by about 65% over the same period, from $9.5 million in 2014 to $3.3 million in 2023. This divergence highlights Bausch Health's robust focus on innovation, while ADMA Biologics appears to be more conservative in its R&D investments. As the industry continues to advance, these strategic choices will likely shape the future trajectories of both companies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025